Bulletin of the World Health Organization

The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV

Lisa O’Brien, Nathan Shaffer, Nalinee Sangrujee & Taiwo O Abimbola

Volume 92, Number 3, March 2014, 162-170

Table 6. Percentage change in incremental costa per woman of Option B+b relative to Option Bc over 5 years postpartum, by CD4+ cell count and for fixed-dose and non-fixed-dose pricing of antiretrovirals

Breastfeeding status and duration CD4+ count 350–500 cells/µl
CD4+ count > 500 cells/µl
Incremental cost, non-fixed-dose pricing (US$) Incremental cost, fixed-dose pricing (US$) Percentage change Incremental cost, non-fixed-dose pricing (US$) Incremental cost, fixed-dose pricing (US$) Percentage change
Breastfeeding
12 months 255 277 9 808 853 6
18 months 9 707 746 6
24 months 9 606 640 6
No breastfeeding 154 170 10 1010 1066 6

a All costs are in 2011 United States dollars (US$).

b Option B+ comprises a triple antiretroviral (ARV) regimen initiated during pregnancy and continued for life.

c Option B comprises a maternal triple ARV regimen, typically consisting of the recommended first-line antiretroviral therapy, during pregnancy and throughout breastfeeding, in combination with 6 weeks of daily nevirapine for the infant, regardless of infant feeding method.